Prostate biopsy in Central Europe: results of a survey of indication, patient preparation and biopsy technique.
OBJECTIVE
We surveyed urologists in Austria, Germany and Switzerland regarding their standard approach to prostate biopsy.


METHODS
Participants of Austrian and German urological meetings were asked to fill out a survey form; additionally, this was mailed to all Swiss urologists.


RESULTS
304 surveys are available for analysis. 97% of participants perform a biopsy if digital rectal examination is abnormal. 63% use 4 ng/ml PSA (prostate-specific antigen) as cut-off. Age-related reference ranges are used by 54%, free PSA by 57%. 22% use PSA density, 55% PSA velocity. Overall 61% require a written consent, with 85, 86 and 25% in Austria, Germany and Switzerland. 96% of the urologists prescribe a quinolone antibiotic with a wide range regarding the start and end of drug therapy. 77% offer some kind of anaesthesia. Periprostatic injection of a local anaesthetic drug is used by 36%, lidocaine gel by 27%. 91% perform the biopsies transrectally under ultrasound guidance. Digitally guided biopsies are used by 11%. Only 3 participants perform perineal biopsies. The mean number of cores per biopsy session is 9.2, the maximum number of cores is 15.3 as a mean. Participants will stop performing any further biopsies if the patient already had a mean of 3.5 biopsy sessions.


CONCLUSIONS
The majority of urologists in Central Europe prescribe a quinolone antibiotic and recommend some type of analgesia. The majority has abandoned the sextant technique and increases the number of cores in the case of rebiopsy. Biopsies are stopped after a mean of 3.5 sessions.
Fink
Klaus G
KG
Department of Urology and Andrology, Paracelsus Medical Private University, Salzburger Landeskliniken, Salzburg, Austria. k.g.fink@salk.at
Schmid
Hans-Peter
HP
Paras
Ljiljana
L
Schmeller
Nikolaus T
NT
D001317:Austria; D001706:Biopsy / Q000379:methods; D005858:Germany; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians'; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011795:Surveys and Questionnaires; D013557:Switzerland